ArticleMolecular cancer therapeutics2026

Nonglycosylated, Legumain-Cleavable ISACs Drive Potent Antitumor Immunotherapy via a Bystander Effect.

Anqi Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.